|
Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC. |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Employment - AstraZeneca/MedImmune |
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Employment - AstraZeneca; Genentech |
Stock and Other Ownership Interests - Genentech |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Patents, Royalties, Other Intellectual Property - MedImmune |
Travel, Accommodations, Expenses - MedImmune |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Patents, Royalties, Other Intellectual Property - MedImmune |